← Evidence library

BIB_440

IO102-IO103 (IDO1 + PD-L1 fixed cancer vaccine) + pembrolizumab — first Phase 3 cancer vaccine trial in first-line advanced cutaneous melanoma (IOB-013/KN-D18, Annals of Oncology 2026): primary PFS endpoint MISSED but PD-L1-negative subgroup shows STRIKING signal (HR 0.54; median PFS 16.6 vs 3.0 months) — fills a ZERO-coverage gap in the contingency landscape. Prior BIBs cover anti-PD-1 ± anti-CTLA-4 checkpoint-only approaches (BIB376/382/438) and personalised mRNA neoantigen vaccines (BIB382 supporting — intismeran autogene/mRNA-4157, Phase 3 INTerpath-001 pending interim). No prior entry c…

Evidence grade

B

Tier

1 (Phase 3 RCT, Annals of Oncolo

Cited by tasks

17, 18, 24

Identifiers

DOI:10.1016/j

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_440/findings.md (research corpus). This page is a short context summary — not individualised medical advice.